NCT06704685View on ClinicalTrials.gov

A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

December 31, 2025

Conditions
ST-segment Elevation Myocardial Infarction (STEMI)
Interventions
DRUG

Butylphthalide

Subjects who were initially diagnosed with STEMI and scheduled for PCI were randomly assigned to one of two groups in a 1:1 ratio: a butylphthalide group and a placebo group.

DRUG

Butylphthalide placebo

Butylphthalide placebo

Sponsors
All Listed Sponsors
collaborator

CSPC Pharmaceutical Group Limited

INDUSTRY

lead

Xiangya Hospital of Central South University

OTHER

NCT06704685 - A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI | Biotech Hunter | Biotech Hunter